Comparative Pharmacology
Head-to-head clinical analysis: OMNICEF versus ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNICEF versus ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER.
OMNICEF vs ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftriaxone is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
300 mg orally twice daily for 10 days; or 600 mg orally once daily for 10 days (for community-acquired pneumonia, acute exacerbations of chronic bronchitis, sinusitis, pharyngitis/tonsillitis, uncomplicated skin infections).
1-2 g IV or IM once daily; maximum 4 g/day. For serious infections, 2 g IV every 12 hours.
None Documented
None Documented
1.7 hours (range 1.2–2.3 h) in healthy adults; prolonged to 3.2–6.6 h in renal impairment (CrCl <30 mL/min); no significant change in hepatic impairment.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged up to 15 hours in elderly; significantly increased in renal impairment (up to 20-30 hours in ESRD).
Renal excretion as unchanged drug: 80-90% (primarily via glomerular filtration and tubular secretion); biliary/fecal: 10-20% (minor).
Renal (33-67% unchanged) and biliary (40-50% unchanged and microbiologically inactive metabolite). Approximately 50% excreted in urine, 50% in feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic